AtriCure, Inc. (NASDAQ:ATRC) has been delivering revenue growth and improved profitability, but the bigger question for investors is whether the latest results had any underlying catalysts strong enough to support the long-term growth potential.
The company reported its Q2 FY26 earnings on July 23, delivering revenue of $153.6 million and an adjusted EPS of $0.18
With healthy growth and a step up in profitability, the company’s revenue and adjusted EPS exceeded the consensus estimates by $1.79 million and $0.16, respectively. This marks a solid 800% EPS beat. Inside the Q2 Results The highlight of the quarter was net income of $9 million, compared with a net loss of $6.2 million in Q2 of 2025.
Thanks to the continued adoption in the pain management franchise, appendage management franchise, and open ablation franchise, the company delivered $27 million in adjusted EBITDA. Copyright: nimon / 123RF Stock Photo Gross margin increased to 77.2% in Q2 2026, up 270 basis points from the Q2 2025 level, primarily driven by product innovation, geographic mix, and efficiencies. The company’s US business was up 14% YoY, with worldwide revenue growing 13%.